Recombinant_JJ Sindbis/Venezuelan_NP Equine_NP Encephalitis_NP Virus_NP Is_VBZ Highly_NP Attenuated_NP and_CC Immunogenic_NP Venezuelan_JJ equine_JJ encephalitis_NN virus_NN (_( VEEV_NP )_) is_VBZ an_DT important_JJ ,_, naturally_RB emerging_VBG zoonotic_JJ virus_NN ._SENT VEEV_NP was_VBD a_DT significant_JJ human_JJ and_CC equine_JJ pathogen_NN for_IN much_JJ of_IN the_DT past_JJ century_NN ,_, and_CC recent_JJ outbreaks_NNS in_IN Venezuela_NP and_CC Colombia_NP (_( 1995_CD )_) ,_, with_IN about_RB 100,000_CD human_JJ cases_NNS ,_, indicate_VBP that_IN this_DT virus_NN still_RB poses_VBZ a_DT serious_JJ public_JJ health_NN threat_NN ._SENT The_DT live_JJ attenuated_JJ TC-83_NP vaccine_NN strain_NN of_IN VEEV_NP was_VBD developed_VBN in_IN the_DT 1960s_NNS using_VBG a_DT traditional_JJ approach_NN of_IN serial_NN passaging_VBG in_IN tissue_NN culture_NN of_IN the_DT virulent_JJ Trinidad_NP donkey_NN (_( TrD_NP )_) strain_NN ._SENT This_DT vaccine_NN presents_VBZ several_JJ problems_NNS ,_, including_VBG adverse_JJ ,_, sometimes_RB severe_JJ reactions_NNS in_IN many_JJ human_JJ vaccinees_NNS ._SENT The_DT TC-83_NP strain_NN also_RB retains_VBZ residual_JJ murine_JJ virulence_NN and_CC is_VBZ lethal_JJ for_IN suckling_VBG mice_NNS after_IN intracerebral_JJ (_( i.c._JJ )_) or_CC subcutaneous_JJ (_( s.c._JJ )_) inoculation_NN ._SENT To_TO overcome_VB these_DT negative_JJ effects_NNS ,_, we_PP developed_VBD a_DT recombinant_JJ ,_, chimeric_JJ Sindbis/VEE_NP virus_NN (_( SIN-83_NP )_) that_WDT is_VBZ more_RBR highly_RB attenuated_VBN ._SENT The_DT genome_NN of_IN this_DT virus_NN encoded_VBD the_DT replicative_JJ enzymes_NNS and_CC the_DT cis-acting_JJ RNA_NP elements_NNS derived_VBN from_IN Sindbis_NP virus_NN (_( SINV_NP )_) ,_, one_CD of_IN the_DT least_JJS human-pathogenic_JJ alphaviruses_NNS ._SENT The_DT structural_JJ proteins_NNS were_VBD derived_VBN from_IN VEEV_NP TC-83_NP ._SENT The_DT SIN-83_NP virus_NN ,_, which_WDT contained_VBD an_DT additional_JJ adaptive_JJ mutation_NN in_IN the_DT nsP2_JJ gene_NN ,_, replicated_VBN efficiently_RB in_IN common_JJ cell_NN lines_NNS and_CC did_VBD not_RB cause_VB detectable_JJ disease_NN in_IN adult_NN or_CC suckling_NN mice_NNS after_IN either_DT i.c._JJ or_CC s.c._JJ inoculation_NN ._SENT However_RB ,_, SIN-83-vaccinated_JJ mice_NNS were_VBD efficiently_RB protected_VBN against_IN challenge_NN with_IN pathogenic_JJ strains_NNS of_IN VEEV_NP ._SENT Our_PP$ findings_NNS suggest_VBP that_IN the_DT use_NN of_IN the_DT SINV_NP genome_NN as_IN a_DT vector_NN for_IN expression_NN of_IN structural_JJ proteins_NNS derived_VBN from_IN more_RBR pathogenic_JJ ,_, encephalitic_JJ alphaviruses_NNS is_VBZ a_DT promising_JJ strategy_NN for_IN alphavirus_NN vaccine_NN development_NN ._SENT Venezuelan_JJ equine_JJ encephalitis_NN virus_NN (_( VEEV_NP )_) is_VBZ a_DT member_NN of_IN the_DT Alphavirus_NP genus_NN in_IN the_DT Togaviridae_NP family_NN ._SENT VEEV_NP is_VBZ an_DT enveloped_VBN virus_NN with_IN a_DT nonsegmented_JJ ,_, positive-sense_JJ RNA_NP genome_NN of_IN approximately_RB 11.5_CD kb_NN ._SENT The_DT 5_CD '_POS two-thirds_NNS of_IN the_DT genome_NN encodes_VBZ four_CD nonstructural_JJ proteins_NNS (_( nsP1_JJ to_TO nsP4_NN )_) that_WDT form_VBP an_DT enzyme_NN complex_NN required_VBN for_IN viral_JJ replication_NN ._SENT After_IN viral_JJ RNA_NP entry_NN into_IN the_DT cytoplasm_NN ,_, a_DT nonstructural_JJ polyprotein_NN is_VBZ translated_VBN directly_RB from_IN the_DT viral_JJ genome_NN and_CC utilized_VBN in_IN the_DT production_NN of_IN a_DT full-length_JJ ,_, negative-sense_JJ replicative_JJ RNA_NP intermediate_NN ._SENT This_DT RNA_NP is_VBZ then_RB used_VBN as_IN a_DT template_NN for_IN synthesis_NN of_IN positive-sense_NN genomic_JJ RNA_NP and_CC for_IN transcription_NN of_IN a_DT subgenomic_JJ 26S_JJ RNA_NP ._SENT The_DT ca_MD ._SENT 4-kb_JJ subgenomic_JJ RNA_NP corresponds_VBZ to_TO the_DT 3_CD '_POS one-third_NN of_IN the_DT viral_JJ genome_NN and_CC is_VBZ translated_VBN into_IN a_DT structural_JJ polyprotein_NN that_WDT is_VBZ proteolytically_RB cleaved_VBN into_IN the_DT capsid_NN and_CC envelope_NN glycoproteins_NNS E2_NP and_CC E1_NP ._SENT Two_CD hundred_CD forty_NN copies_NNS of_IN the_DT capsid_NN protein_NN combine_NN with_IN the_DT genomic_JJ viral_JJ RNA_NP to_TO form_VB an_DT icosahedral_JJ nucleocapsid_NN ._SENT Finally_RB ,_, the_DT nucleocapsid_JJ buds_NNS from_IN the_DT plasma_NN membrane_NN to_TO acquire_VB a_DT lipid_NN envelope_NN with_IN embedded_VBN protein_NN spikes_NNS containing_VBG E1-E2_JJ heterodimers_NNS ._SENT VEEV_NP was_VBD a_DT significant_JJ human_JJ and_CC equine_JJ pathogen_NN for_IN much_JJ of_IN the_DT past_JJ century_NN ,_, and_CC recent_JJ epidemics_NNS indicate_VBP that_IN VEEV_NP still_RB represents_VBZ a_DT serious_JJ public_JJ health_NN threat_NN ._SENT Furthermore_RB ,_, VEEV_NP is_VBZ a_DT potential_JJ biological_JJ warfare_NN and_CC terrorism_NN threat_NN ._SENT Alphaviruses_NNS in_IN the_DT Venezuelan_JJ equine_JJ encephalitis_NN (_( VEE_NP )_) complex_NN are_VBP serologically_RB classified_VBN into_IN six_CD distinct_JJ antigenic_JJ subtypes_NNS ._SENT Historically_RB ,_, only_JJ members_NNS of_IN subtypes_NNS IAB_NP and_CC IC_NP were_VBD associated_VBN with_IN major_JJ epidemics_NNS and_CC equine_JJ epizootics_NNS ._SENT During_IN the_DT most_RBS recent_JJ major_JJ outbreak_NN in_IN Venezuela_NP and_CC Colombia_NP (_( 1995_CD )_) involving_VBG subtype_NN IC_NP VEEV_NP ,_, about_RB 100,000_CD human_JJ cases_NNS occurred_VBD ,_, with_IN more_JJR than_IN 300_CD fatal_JJ encephalitis_NN cases_NNS estimated_VBD ._SENT VEEV_NP infection_NN of_IN mice_NNS leads_VBZ to_TO a_DT biphasic_JJ disease_NN with_IN initial_JJ replication_NN in_IN lymphoid_JJ tissues_NNS followed_VBN by_IN viremia_NN and_CC penetration_NN into_IN the_DT central_JJ nervous_JJ system_NN (_( CNS_NP )_) ,_, where_WRB the_DT virus_NN replicates_VBZ until_IN the_DT death_NN of_IN the_DT infected_JJ animal_NN (_( -_: ,_, )_) ._SENT The_DT result_NN of_IN the_DT CNS_NP infection_NN is_VBZ acute_JJ meningoencephalitis_NN that_WDT leads_VBZ to_TO massive_JJ death_NN of_IN neuronal_JJ cells_NNS ._SENT During_IN VEEV_NP epizootics_NNS ,_, equine_JJ mortality_NN due_JJ to_TO encephalitis_NN can_MD reach_VB 83_CD %_NN ;_: in_IN humans_NNS ,_, while_IN the_DT overall_JJ mortality_NN rate_NN is_VBZ low_JJ (_( <1_JJ %_NN )_) ,_, neurological_JJ disease_NN including_VBG disorientation_NN ,_, ataxia_NN ,_, mental_JJ depression_NN ,_, and_CC convulsions_NNS can_MD be_VB detected_VBN in_IN up_IN to_TO 14_CD %_NN of_IN infected_JJ individuals_NNS ,_, especially_RB children_NNS ._SENT Sequelae_NNS of_IN VEE-related_JJ clinical_JJ encephalitis_NN in_IN humans_NNS and_CC rats_NNS are_VBP also_RB described_VBN ._SENT The_DT predominant_JJ pathological_JJ findings_NNS in_IN fatal_JJ human_JJ VEE_NP cases_NNS reveal_VBP the_DT following_NN :_: (_( i_NP )_) in_IN the_DT CNS_NP ,_, edema_NN ,_, congestion_NN ,_, hemorrhages_NNS ,_, vasculitis_NN ,_, meningitis_NN and_CC encephalitis_NN ;_: (_( ii_NP )_) in_IN the_DT lungs_NNS ,_, interstitial_JJ pneumonia_NN ,_, alveolar_JJ hemorrhage_NN ,_, congestion_NN ,_, and_CC edema_NN ;_: (_( iii_NP )_) in_IN lymphoid_JJ tissue_NN ,_, follicular_JJ necrosis_NN and_CC lymphocyte_NN depletion_NN ;_: and_CC (_( iv_NN )_) in_IN the_DT liver_NN ,_, diffuse_JJ hepatocellular_JJ degeneration_NN ._SENT A_DT small_JJ animal_NN (_( mouse_NN )_) model_NN for_IN VEE-induced_JJ encephalitis_NN and_CC lymphotropism_NN is_VBZ well_RB established_VBN ;_: however_RB ,_, mice_NNS do_VBP not_RB develop_VB the_DT pulmonary_JJ and_CC hepatic_JJ symptoms_NNS that_WDT were_VBD described_VBN at_IN high_JJ rates_NNS (_( 91_CD and_CC 61_CD %_NN ,_, respectively_RB )_) in_IN fatal_JJ human_JJ VEE_NP cases_NNS ._SENT The_DT live-attenuated_JJ TC-83_NP vaccine_NN strain_NN (_( TC-83_NP )_) was_VBD developed_VBN 4_CD decades_NNS ago_RB by_IN serial_NN passaging_VBG of_IN the_DT virulent_JJ ,_, subtype_NN IAB_NP Trinidad_NP donkey_NN (_( TrD_NP )_) VEEV_NP strain_NN in_IN guinea_NN pig_NN heart_NN cell_NN cultures_NNS ._SENT Currently_RB ,_, TC-83_NP is_VBZ still_RB the_DT only_JJ VEEV_NP strain_NN available_JJ for_IN vaccination_NN of_IN laboratory_NN workers_NNS and_CC military_JJ personnel_NNS ._SENT More_JJR than_IN 8,000_CD humans_NNS have_VBP been_VBN vaccinated_VBN during_IN the_DT past_JJ 4_CD decades_NNS ._SENT The_DT cumulative_JJ data_NNS unambiguously_RB demonstrated_VBD that_IN nearly_RB 40_CD %_NN of_IN vaccinated_VBN people_NNS develop_VBP a_DT disease_NN with_IN some_DT symptoms_NNS typical_JJ of_IN natural_JJ VEEV_NP infection_NN ,_, including_VBG febrile_JJ ,_, systemic_JJ illness_NN and_CC other_JJ adverse_JJ effects_NNS ._SENT The_DT TC-83_NP vaccine_NN has_VBZ also_RB been_VBN used_VBN for_IN immunization_NN of_IN equines_NNS and_CC can_MD lead_VB to_TO febrile_JJ clinical_JJ illness_NN with_IN viremia_NN levels_NNS that_WDT are_VBP potentially_RB sufficient_JJ to_TO infect_VB mosquitoes_NNS and_CC initiate_VB a_DT transmission_NN cycle_NN ._SENT These_DT findings_NNS indicate_VBP significant_JJ residual_JJ virulence_NN of_IN TC-83_NP strain_NN in_IN both_DT humans_NNS and_CC horses_NNS ._SENT Residual_JJ virulence_NN has_VBZ also_RB been_VBN detected_VBN in_IN mice_NNS ,_, where_WRB TC-83_NP was_VBD uniformly_RB lethal_JJ for_IN the_DT C3H/HeN_NP strain_NN after_IN intracerebral_JJ (_( i.c._JJ )_) inoculation_NN and_CC produced_VBD clinical_JJ illness_NN in_IN BALB/c_NP and_CC C3H/HeN_NP mice_NNS for_IN almost_RB 14_CD days_NNS after_IN subcutaneous_JJ (_( s.c._JJ )_) inoculation_NN ._SENT A_DT formalin-inactivated_JJ version_NN of_IN the_DT TC-83_NP vaccine_NN ,_, C-84_NP ,_, is_VBZ used_VBN for_IN individuals_NNS who_WP fail_VBP to_TO seroconvert_VB to_TO TC-83_NP ._SENT However_RB ,_, repeated_JJ boosters_NNS with_IN C-84_NP are_VBP required_VBN to_TO generate_VB and_CC maintain_VB an_DT effective_JJ immune_JJ response_NN ,_, and_CC the_DT induced_VBD neutralizing_VBG antibodies_NNS do_VBP not_RB persist_VB for_IN a_DT long_JJ time_NN ._SENT A_DT more_RBR promising_JJ candidate_NN vaccine_NN was_VBD described_VBN recently_RB ,_, when_WRB attenuation_NN of_IN the_DT VEEV_NP TrD_NP strain_NN was_VBD achieved_VBN by_IN the_DT introduction_NN of_IN lethal_JJ mutations_NNS into_IN the_DT PE2_JJ furin_NN cleavage_NN site_NN of_IN an_DT infectious_JJ cDNA_NN clone_NN ,_, followed_VBN by_IN selection_NN of_IN a_DT second-site_JJ suppressor_NN mutation_NN in_IN the_DT E1_JJ glycoprotein_NN ._SENT This_DT virus_NN is_VBZ highly_RB attenuated_VBN for_IN laboratory_NN rodents_NNS ._SENT This_DT strategy_NN minimized_VBD the_DT potential_NN for_IN direct_JJ reversion_NN to_TO virulence_NN ._SENT However_RB ,_, the_DT potential_NN for_IN reversion_NN to_TO wild-type_NN virulence_NN via_IN compensatory_JJ mutations_NNS remains_VBZ ._SENT To_TO further_RBR overcome_VB the_DT problem_NN of_IN possible_JJ reversion_NN to_TO wild-type_NN virulence_NN of_IN live-attenuated_JJ VEEV_NP vaccine_NN strains_NNS ,_, we_PP have_VBP applied_VBN an_DT alternative_JJ approach_NN using_VBG a_DT recombinant_JJ virus_NN capable_JJ of_IN inducing_VBG a_DT protective_JJ immune_JJ response_NN ._SENT Utilizing_VBG the_DT genome_NN of_IN Sindbis_NP virus_NN (_( SINV_NP )_) ,_, a_DT relatively_RB human-nonpathogenic_JJ alphavirus_NN ,_, as_IN a_DT vector_NN ,_, we_PP developed_VBD a_DT chimeric_JJ SIN/VEE_NP virus_NN expressing_VBG all_DT of_IN the_DT structural_JJ proteins_NNS of_IN the_DT TC-83_NP strain_NN ._SENT This_DT recombinant_JJ virus_NN ,_, SIN-83_NP ,_, replicated_VBN to_TO high_JJ titers_NNS in_IN cell_NN culture_NN and_CC protected_JJ mice_NNS against_IN lethal_JJ challenge_NN with_IN high_JJ doses_NNS of_IN recently_RB isolated_VBN ,_, naturally_RB circulating_VBG subtype_NN IC_NP and_CC ID_JJ strains_NNS of_IN VEEV_NP ._SENT A_DT distinguishing_VBG feature_NN of_IN this_DT SIN-83_NP chimeric_JJ virus_NN is_VBZ its_PP$ inability_NN to_TO cause_VB any_DT detectable_JJ clinical_JJ disease_NN in_IN either_DT adult_NN or_CC weanling_NN mice_NNS after_IN either_DT s.c._JJ or_CC i.c._JJ inoculation_NN ._SENT Cell_NN cultures_NNS ._SENT |_SYM BHK-21_NP cells_NNS were_VBD obtained_VBN from_IN the_DT American_NP Type_NP Culture_NP Collection_NP (_( Rockville_NP ,_, Md._NP )_) ._SENT Vero_NP cells_NNS were_VBD kindly_RB provided_VBN by_IN Charles_NP M._NP Rice_NP (_( Rockefeller_NP University_NP ,_, New_NP York_NP ,_, N.Y._NP )_) ._SENT Both_CC cell_NN lines_NNS were_VBD propagated_VBN in_IN Alpha_NP minimal_JJ essential_JJ medium_NN (_( MEM_NP )_) supplemented_VBD with_IN 10_CD %_NN fetal_JJ bovine_JJ serum_NN (_( FBS_NP )_) and_CC vitamins_NNS ._SENT Mice_NNS ._SENT |_SYM Weanling_NP (_( male_JJ and_CC female_JJ )_) NIH_NP Swiss_NP mice_NNS purchased_VBN from_IN Harlan_NP (_( Indianapolis_NP ,_, Ind._NP )_) were_VBD maintained_VBN for_IN 6_CD days_NNS after_IN birth_NN in_IN a_DT BSL-3_NP facility_NN prior_RB to_TO experimental_JJ infection_NN ._SENT Plasmid_NP constructs_VBZ ._SENT |_SYM All_DT plasmids_NNS were_VBD constructed_VBN by_IN standard_JJ recombinant_JJ DNA_NN techniques_NNS ._SENT The_DT parental_JJ pToto1101_JJ plasmid_NN ,_, encoding_VBG the_DT SINV_NP genome_NN ,_, and_CC the_DT pTC-83_JJ plasmid_NN ,_, encoding_VBG the_DT genome_NN of_IN VEEV_NP TC-83_NP ,_, were_VBD obtained_VBN from_IN Charles_NP M._NP Rice_NP (_( Rockefeller_NP University_NP ,_, New_NP York_NP ,_, N.Y._NP )_) and_CC Richard_NP Kinney_NP (_( Centers_NPS for_IN Disease_NP Control_NP ,_, Fort_NP Collins_NP ,_, Colo._NP )_) ,_, respectively_RB ._SENT Fragments_NNS containing_VBG the_DT SINV_NP subgenomic_JJ promoter_NN and_CC the_DT 5_CD '_POS untranslated_JJ region_NN (_( UTR_NP )_) of_IN the_DT VEEV_NP subgenomic_NP RNA_NP were_VBD generated_VBN by_IN PCR_NP amplification_NN ,_, cloned_VBN into_IN the_DT pRS2_JJ plasmid_NN for_IN sequencing_NP ,_, and_CC then_RB used_VBN for_IN generating_VBG the_DT cDNA_NN clone_NN of_IN the_DT chimeric_JJ SIN-83S_NP virus_NN genome_NN ._SENT The_DT sequence_NN of_IN the_DT junction_NN region_NN between_IN the_DT SINV_NP and_CC VEEV_NP sequences_NNS is_VBZ shown_VBN in_IN Fig._NN ._SENT The_DT construct_NN ,_, pSIN-83S_NNS ,_, contained_VBD the_DT promoter_NN for_IN SP6_NP RNA_NP polymerase_NN ,_, followed_VBN by_IN nucleotides_NNS (_( nt_NN )_) 1_CD to_TO 7601_CD of_IN the_DT SINV_NP genome_NN ,_, nt_VBG 7536_CD to_TO 11382_CD of_IN VEEV_NP TC-83_NP (_( with_IN an_DT additional_JJ C->T_NP mutation_NN of_IN nt_NN 7555_CD )_) ,_, an_DT AGGCCTTGGG_NP sequence_NN ,_, and_CC a_DT 355-nt_JJ sequence_NN containing_VBG the_DT SINV_NP 3'UTR_NP (_( starting_VBG from_IN nt_NN 11394_CD )_) ,_, poly(A)_NN followed_VBD by_IN an_DT XhoI_NP restriction_NN site_NN ._SENT A_DT map_NN and_CC se-quences_NNS of_IN the_DT plasmid_NN are_VBP available_JJ from_IN the_DT authors_NNS upon_IN request_NN ._SENT pSIN-83_NN was_VBD different_JJ from_IN pSIN-83S_NNS by_IN a_DT single_JJ point_NN mutation_NN at_IN nt_NN 4065_CD ,_, changing_VBG Ser795_NP in_IN nsP2_NN to_TO Thr_NP ._SENT Plasmids_NP pZPC_NP and_CC pSH_NP ,_, containing_VBG infectious_JJ cDNAs_NNS of_IN VEEV_NP strains_NNS ZPC738_NP (_( subtype_NN ID_NN )_) and_CC SH3_NP (_( subtype_NN IC_NP )_) ,_, respectively_RB ,_, will_MD be_VB described_VBN elsewhere_RB (_( a_DT publication_NN describing_VBG these_DT two_CD clones_NNS is_VBZ in_IN preparation_NN )_) ._SENT The_DT ZPC738_NP strain_NN was_VBD isolated_VBN from_IN a_DT sentinel_NN hamster_NN exposed_VBN in_IN a_DT tropical_JJ lowland_JJ forest_NN of_IN Zulia_NP State_NP ,_, Venezuela_NP ,_, in_IN 1997_CD ,_, and_CC strain_VBP SH3_NP was_VBD isolated_VBN from_IN a_DT febrile_JJ human_NN during_IN the_DT 1992-3_CD Venezuelan_JJ epidemic/epizootic_NN ._SENT RNA_NP transcription_NN and_CC transfection_NN ._SENT |_SYM Plasmids_NP were_VBD purified_VBN by_IN centrifugation_NN in_IN CsCl_NP gradients_NNS ._SENT Prior_RB to_TO transcription_NN ,_, they_PP were_VBD linearized_VBN by_IN the_DT restriction_NN enzymes_NNS immediately_RB downstream_RB from_IN the_DT poly(A)_JJ sequences_NNS in_IN the_DT genomes_NNS ._SENT RNAs_NNS were_VBD synthesized_VBN by_IN SP6_NP RNA_NP polymerase_NN (_( Invitrogen_NP )_) or_CC T7_JJ RNA_NP polymerase_NN (_( Epicentre_NP )_) (_( in_IN case_NN of_IN the_DT TC-83-coding_NP plasmid_NP )_) in_IN the_DT presence_NN of_IN cap_NN analog_NN ._SENT The_DT yield_NN and_CC integrity_NN of_IN transcripts_NNS were_VBD monitored_VBN by_IN gel_NN electrophoresis_NN in_IN nondenaturing_JJ conditions_NNS ._SENT For_IN electroporation_NN ,_, aliquots_NNS of_IN transcription_NN reactions_NNS were_VBD used_VBN without_IN additional_JJ purification_NN ,_, and_CC RNAs_NP were_VBD transfected_VBN into_IN BHK-21_JJ cells_NNS using_VBG previously_RB described_VBN conditions_NNS ._SENT Viruses_NNS were_VBD harvested_VBN after_IN cytopathic_JJ effect_NN (_( CPE_NP )_) development_NN ,_, usually_RB 24_CD h_NN postelectroporation_NN ._SENT Viral_JJ replication_NN analysis_NN ._SENT |_SYM Cells_NP were_VBD seeded_VBN at_IN a_DT concentration_NN of_IN 5_CD x_SYM 105_CD cells/35-mm-diameter_NN dish_NN ._SENT After_IN 4_CD h_NN of_IN incubation_NN at_IN 37C_JJ ,_, monolayers_NNS were_VBD infected_VBN at_IN an_DT appropriate_JJ multiplicity_NN of_IN infection_NN (_( MOI_NP )_) (_( as_RB indicated_VBN in_IN figure_NN legends_NNS )_) for_IN 1_CD h_NN at_IN 37C_JJ ,_, and_CC then_RB the_DT inoculum_NN was_VBD replaced_VBN with_IN 1_CD ml_NN of_IN complete_JJ medium_NN ._SENT At_IN selected_JJ times_NNS postinfection_NN ,_, media_NNS were_VBD replaced_VBN by_IN fresh_JJ media_NNS ,_, and_CC titers_NNS of_IN virus_NN in_IN the_DT harvested_VBN samples_NNS were_VBD determined_VBN by_IN plaque_NN assay_NN on_IN BHK-21_JJ cells_NNS ._SENT RNA_NP analysis_NN ._SENT |_SYM The_DT protocol_NN used_VBN for_IN labeling_VBG SINV-specific_NP RNAs_NP with_IN [_SYM 3H]uridine_JJ in_IN the_DT presence_NN of_IN dactinomycin_NN is_VBZ described_VBN in_IN the_DT legend_NN to_TO Fig._NN ._SENT RNAs_NNS were_VBD isolated_VBN from_IN the_DT cells_NNS by_IN using_VBG TRIzol_NP reagent_NN ,_, as_RB recommended_VBN by_IN the_DT manufacturer_NN (_( Gibco-BRL_NP ,_, Bethesda_NP ,_, Md._NP )_) ,_, denatured_VBN with_IN glyoxal_NN in_IN dimethyl_NN sulfoxide_NN ,_, and_CC analyzed_VBD by_IN agarose_JJ gel_NN electrophoresis_NN using_VBG the_DT previously_RB described_VBN conditions_NNS ._SENT Analysis_NN of_IN protein_NN synthesis_NN ._SENT |_SYM BHK-21_NP cells_NNS were_VBD seeded_VBN into_IN 6-well_JJ dishes_NNS at_IN a_DT concentration_NN of_IN 5_CD x_SYM 105_CD cells/well_NN ._SENT Four_CD hours_NNS later_RBR ,_, the_DT cells_NNS were_VBD infected_VBN with_IN different_JJ viruses_NNS at_IN an_DT MOI_NP of_IN 10_CD PFU/cell_NN in_IN 200_CD mul_NN of_IN Alpha_NP MEM_NP supplemented_VBD with_IN 1_CD %_NN FBS_NP at_IN room_NN temperature_NN for_IN 1_CD h._NP Media_NP were_VBD then_RB replaced_VBN with_IN Alpha_NP MEM_NP containing_VBG 10_CD %_NN FBS_NP ,_, and_CC incubation_NN was_VBD continued_VBN at_IN 37C_JJ ._SENT At_IN 12_CD h_NN postinfection_NN ,_, the_DT cells_NNS were_VBD washed_VBN three_CD times_NNS with_IN phosphate-buffered_JJ saline_NN (_( PBS_NP )_) and_CC then_RB incubated_VBN for_IN 30_CD min_NN at_IN 37C_JJ in_IN 1_CD ml_NN of_IN RPMI_NP medium_NN lacking_VBG methionine_NN ,_, supplemented_VBN with_IN 0.1_CD %_NN FBS_NP and_CC 20_CD muCi_NNS of_IN [_SYM 35S]methionine_JJ ._SENT After_IN the_DT incubation_NN ,_, cells_NNS were_VBD scraped_VBN from_IN the_DT dish_NN into_IN PBS_NP ,_, pelleted_VBN by_IN centrifugation_NN ,_, and_CC dissolved_VBN in_IN 200_CD mul_NN of_IN standard_JJ loading_NN buffer_NN ._SENT Aliquots_NNS of_IN the_DT samples_NNS were_VBD analyzed_VBN on_IN sodium_NN dodecyl_NN sulfate-10_NN %_NN polyacrylamide_NN gels_NNS ._SENT After_IN electrophoresis_NN ,_, gels_NNS were_VBD dried_VBN and_CC analyzed_VBN by_IN autoradiography_NN ._SENT Immunization_NN and_CC challenge_NN with_IN virulent_JJ VEEV_NP ._SENT |_SYM Weanling_NP female_JJ 6-day-old_JJ mice_NNS were_VBD inoculated_VBN s.c._NN with_IN VEE_NP TC-83_NP or_CC SIN-83_NP viruses_NNS at_IN doses_NNS of_IN 103_CD ,_, 104_CD ,_, 105_CD or_CC 106_CD PFU_NN in_IN a_DT total_JJ volume_NN of_IN 100_CD mul_NN of_IN PBS_NP ._SENT After_IN vaccination_NN ,_, each_DT cohort_NN of_IN 10_CD animals_NNS was_VBD maintained_VBN for_IN 21_CD days_NNS without_IN any_DT manipulation_NN ._SENT Immunized_VBN animals_NNS were_VBD then_RB challenged_VBN with_IN VEEV_NP subtype_NN ID_NN strain_NN ZPC738_NP (_( half_NN of_IN the_DT animals_NNS )_) or_CC subtype_NN IC_NP strain_NN SH3_NP (_( half_NN of_IN the_DT animals_NNS )_) by_IN subcutaneous_JJ injection_NN into_IN the_DT medial_JJ thigh_NN with_IN 106_CD PFU_NN (_( ca_MD ._SENT 106_CD 50_CD %_NN lethal_JJ doses_NNS [_SYM LD50_NP ]_SYM )_) per_IN animal_NN in_IN 0.1_CD ml_NN of_IN PBS_NP ._SENT Five_CD nonvaccinated_JJ ,_, 4-week-old_JJ mice_NNS were_VBD challenged_VBN in_IN the_DT same_JJ manner_NN at_IN the_DT same_JJ time_NN ,_, with_IN each_DT strain_NN ._SENT Mice_NNS were_VBD observed_VBN twice_RB daily_JJ for_IN clinical_JJ illness_NN (_( ruffled_VBN ,_, depressed_VBN ,_, anorexia_NN ,_, and/or_CC paralysis_NN )_) and/or_CC death_NN ._SENT Other_JJ groups_NNS of_IN mice_NNS were_VBD vaccinated_VBN with_IN the_DT described_VBN above_IN doses_NNS of_IN VEE_NP TC-83_NP or_CC SIN-83_NP viruses_NNS and_CC kept_VBN for_IN 28_CD days_NNS postvaccination_NN for_IN final_JJ bleeding_NN that_WDT was_VBD performed_VBN ,_, after_IN isoflurane_NN narcosis_NN ,_, using_VBG cardiac_JJ puncture_NN ._SENT Collected_VBN serum_NN was_VBD heat_NN inactivated_VBN at_IN 56C_NN for_IN 30_CD min_NN and_CC kept_VBD frozen_VBN at_IN -70C_NN until_IN further_JJR serological_JJ tests_NNS ._SENT Antibody_NN assays_NNS ._SENT |_SYM Plaque_NP reduction_NN neutralization_NN tests_NNS were_VBD performed_VBN on_IN BHK-21_JJ monolayers_NNS ._SENT A_DT stock_NN of_IN VEEV_NP TC-83_NP was_VBD incubated_VBN for_IN 1_CD h_NN at_IN 37C_JJ with_IN different_JJ dilutions_NNS of_IN sera_NN taken_VBN individually_RB from_IN mice_NNS infected_VBN with_IN VEE_NP TC-83_NP or_CC SIN-83_NP viruses_NNS ._SENT Then_RB cell_NN monolayers_NNS were_VBD incubated_VBN with_IN a_DT virus-serum_NN mixture_NN for_IN 1_CD h_NN at_IN 37C_JJ ,_, overlaid_VBN with_IN 0.5_CD %_NN agarose_NN ,_, maintained_VBN for_IN 36_CD h_NN at_IN 37C_JJ ,_, and_CC stained_VBD with_IN crystal_NN violet_NN ._SENT Comparative_JJ virulence_NN of_IN VEE_NP TC-83_NP and_CC SIN-83_NP ._SENT |_SYM Six-day-old_JJ mice_NNS (_( male_JJ and_CC female_JJ )_) were_VBD inoculated_VBN i.c._JJ or_CC s.c._JJ with_IN 2_CD x_NN 104_CD ,_, 2_CD x_SYM 105_CD ,_, or_CC 2_CD x_SYM 106_CD PFU_NP of_IN VEE_NP TC-83_NP and_CC SIN-83_NP viruses_NNS ._SENT Final_JJ volumes_NNS per_IN animal_NN were_VBD 20_CD mul_NN (_( in_IN PBS_NP )_) for_IN i.c._NN and_CC 100_CD mul_NN for_IN the_DT s.c._JJ inoculation_NN route_NN ._SENT Animals_NNS were_VBD monitored_VBN twice_RB daily_RB as_RB described_VBN previously_RB for_IN at_IN least_JJS 2_CD months_NNS ._SENT Long-term_JJ pathogenicity_NN study_NN ._SENT |_SYM Six-day-old_NP NIH_NP Swiss_JJ mice_NNS (_( male_JJ and_CC female_JJ )_) were_VBD inoculated_VBN s.c._JJ into_IN the_DT medial_JJ thigh_NN with_IN 2_CD x_SYM 106_CD PFU_NP of_IN VEEV_NP TC-83_NP or_CC with_IN SIN-83_NP virus_NN (_( in_IN 100_CD mul_NN of_IN PBS_NP )_) ;_: 10_CD animals_NNS were_VBD used_VBN per_IN virus_NN ,_, and_CC 6_CD noninfected_JJ animals_NNS of_IN the_DT same_JJ age_NN were_VBD included_VBN as_IN controls_NNS ._SENT The_DT body_NN weight_NN of_IN each_DT animal_NN was_VBD determined_VBN weekly_RB for_IN 6_CD weeks_NNS ,_, starting_VBG on_IN day_NN 7_CD of_IN age_NN (_( day_NN 1_CD postinfection_NN )_) ._SENT Weights_NNS of_IN animals_NNS that_WDT died_VBD were_VBD excluded_VBN from_IN the_DT study_NN ._SENT Recombinant_JJ SIN-83_NP virus_NN ._SENT |_SYM Using_VBG previously_RB generated_VBN infectious_JJ cDNA_NN copies_NNS of_IN the_DT SINV_NP and_CC VEEV_NP genomes_NNS ,_, we_PP designed_VBD a_DT recombinant_JJ virus_NN named_VBN SIN-83_NP and_CC tested_VBD its_PP$ pathogenicity_NN and_CC ability_NN to_TO induce_VB a_DT protective_JJ immune_JJ response_NN against_IN VEEV_NP challenge_NN ._SENT The_DT cis-acting_JJ RNA_NP elements_NNS of_IN the_DT recombinant_JJ genome_NN ,_, which_WDT are_VBP required_VBN for_IN replication_NN and_CC transcription_NN of_IN the_DT subgenomic_JJ RNA_NP (_( 5_CD '_POS UTR_NP ,_, 3_CD '_'' UTR_NP ,_, and_CC the_DT subgenomic_JJ promoter_NN )_) ,_, were_VBD derived_VBN from_IN SINV_NP (_( see_VB Materials_NNS and_CC Methods_NNS )_) ._SENT All_DT of_IN the_DT nonstructural_JJ protein_NN genes_NNS were_VBD SINV_NP specific_NN as_IN well_RB ._SENT Structural_JJ genes_NNS and_CC the_DT 5_CD '_POS UTR_NP of_IN the_DT subgenomic_JJ RNA_NP were_VBD acquired_VBN from_IN the_DT VEEV_NP TC-83_NP genome_NN ._SENT This_DT strategy_NN of_IN virus_NN design_NN was_VBD developed_VBN to_TO maintain_VB the_DT optimal_JJ combinations_NNS of_IN (_( i_NP )_) factors_NNS essential_JJ for_IN RNA_NP replication_NN ,_, which_WDT include_VBP replicative_JJ enzymes_NNS and_CC recognized_VBD RNA_NP sequences_NNS ,_, and_CC (_( ii_NN )_) factors_NNS required_VBN for_IN efficient_JJ translation_NN of_IN the_DT subgenomic_JJ RNA_NP (_( the_DT sequence_NN and_CC secondary_JJ structure_NN of_IN the_DT 26S_JJ 5_CD '_POS UTR_NN )_) ._SENT The_DT promoter_NN element_NN ,_, located_VBN upstream_RB of_IN the_DT subgenomic_JJ RNA_NP transcription_NN start_NN ,_, and_CC the_DT four_CD 5'terminal_JJ nucleotides_NNS of_IN the_DT subgenomic_JJ RNA_NP were_VBD designed_VBN to_TO be_VB SINV_NP specific_NN ,_, because_IN they_PP represent_VBP the_DT end_NN of_IN nsP4_NN and_CC the_DT termination_NN codon_NN of_IN the_DT nsP-coding_JJ open_JJ reading_NN frame_NN ._SENT The_DT additional_JJ C->T_NP mutation_NN was_VBD introduced_VBN into_IN position_NN 24_CD of_IN the_DT 26S_JJ 5_CD '_POS UTR_NN to_TO compensate_VB for_IN the_DT G->A_NP mutation_NN in_IN position_NN 4_CD and_CC to_TO maintain_VB the_DT computer-predicted_JJ 5_CD '_POS terminal_JJ secondary_JJ structure_NN of_IN the_DT SIN-83S_NP subgenomic_JJ RNA_NP close_NN to_TO that_DT of_IN the_DT VEEV_NP subgenomic_JJ RNA_NP ._SENT The_DT in_IN vitro-synthesized_JJ RNAs_NP of_IN VEE_NP TC-83_NP ,_, SIN-83S_NP (_( the_DT initial_JJ construct_NN )_) ,_, and_CC SIN_NP Toto1101_NP viruses_NNS were_VBD electroporated_VBN into_IN BHK-21_JJ cells_NNS ._SENT All_DT of_IN the_DT RNAs_NP had_VBD similar_JJ infectivity_NN (_( data_NNS not_RB shown_VBN )_) ,_, and_CC rescued_VBD viruses_NNS were_VBD harvested_VBN 24_CD h_NN later_RBR and_CC used_VBD for_IN all_DT subsequent_JJ experiments_NNS ._SENT By_IN that_DT time_NN ,_, all_DT cells_NNS exhibited_VBD profound_JJ cytopathic_JJ effects_NNS (_( CPE_NP )_) ._SENT We_PP noticed_VBD that_IN the_DT original_JJ SIN-83S_NP virus_NN ,_, recovered_VBN after_IN RNA_NP transfection_NN ,_, initially_RB had_VBD a_DT small-plaque_NN phenotype_NN that_WDT was_VBD unstable_JJ ._SENT The_DT large_JJ plaques_NNS developed_VBN after_IN one_CD passage_NN and_CC rapidly_RB became_VBD dominant_JJ ._SENT The_DT entire_JJ viral_JJ genome_NN from_IN one_CD large_JJ plaque-forming_JJ isolate_NN (_( SIN-83_NP lp_NP )_) was_VBD sequenced_JJ ,_, and_CC the_DT only_JJ difference_NN with_IN respect_NN to_TO the_DT original_JJ sequence_NN was_VBD identified_VBN at_IN position_NN 4065_CD ,_, leading_VBG to_TO a_DT S795->T_NP mutation_NN in_IN nsP2_NN ._SENT This_DT mutation_NN was_VBD introduced_VBN into_IN the_DT pSIN-83S_NP plasmid_NP ,_, which_WDT was_VBD then_RB named_VBN pSIN-83_NN ._SENT The_DT SIN-83_NP virus_NN ,_, rescued_VBN from_IN this_DT cDNA_NN ,_, had_VBD a_DT large-plaque_NN phenotype_NN and_CC was_VBD indistinguishable_JJ from_IN the_DT variant_JJ SIN-83_NP lp_NN ,_, based_VBN on_IN plaque_NN morphology_NN and_CC replication_NN kinetics_NNS ._SENT It_PP also_RB replicated_VBD at_IN a_DT significantly_RB higher_JJR rate_NN and_CC to_TO higher_JJR titers_NNS than_IN the_DT original_JJ SIN-83S_NP virus_NN ._SENT This_DT SIN-83_NP variant_NN was_VBD used_VBN for_IN the_DT next_JJ experiments_NNS ._SENT Replication_NN of_IN SIN-83_NP recombinant_JJ virus_NN ._SENT |_SYM In_IN the_DT initial_JJ experiments_NNS ,_, we_PP compared_VBD the_DT basic_JJ replication_NN characteristics_NNS of_IN the_DT rescued_VBN recombinant_JJ SIN-83_NP virus_NN with_IN those_DT of_IN VEEV_NP TC-83_NP and_CC SINV_NP Toto1101_NP ._SENT We_PP analyzed_VBD the_DT ability_NN of_IN all_DT three_CD viruses_NNS to_TO replicate_VB in_IN commonly_RB used_VBN cell_NN lines_NNS and_CC the_DT synthesis_NN of_IN virus-specific_JJ RNAs_NP and_CC proteins_NNS during_IN viral_JJ replication_NN ._SENT All_DT three_CD viruses_NNS were_VBD able_JJ to_TO replicate_VB in_IN both_DT BHK-21_NP and_CC Vero_NP cells_NNS (_( Fig._NN and_CC B_NN )_) with_IN similar_JJ efficiencies_NNS ,_, but_CC they_PP caused_VBD very_RB different_JJ morphological_JJ changes_NNS in_IN the_DT cells_NNS during_IN CPE_NN development_NN ._SENT Besides_RB ,_, the_DT SINV_NP Toto1101-infected_NP Vero_NP and_CC BHK-21_NP cells_NNS died_VBD noticeably_RB faster_RBR than_IN those_DT infected_JJ with_IN VEEV_NP TC-83_NP ._SENT However_RB ,_, the_DT release_NN of_IN SINV_NP Toto1101_NP was_VBD slower_JJR ,_, particularly_RB in_IN Vero_NP cells_NNS ,_, and_CC final_JJ titers_NNS in_IN the_DT media_NNS were_VBD always_RB substantially_RB lower_RBR compared_VBN to_TO those_DT of_IN VEEV_NP TC-83_NP ._SENT SIN-83_NP and_CC SINV_NP Toto1101_NP developed_VBD CPE_NN at_IN similar_JJ rates_NNS and_CC with_IN comparable_JJ changes_NNS in_IN cell_NN morphology_NN ._SENT The_DT chimeric_JJ virus_NN replicated_VBN better_RBR than_IN SINV_NP ,_, but_CC not_RB to_TO the_DT same_JJ titers_NNS as_IN VEEV_NP TC-83_NP (_( Fig._NN and_CC B_NN )_) ._SENT Analysis_NN of_IN viral_JJ protein_NN synthesis_NN demonstrated_VBD that_IN the_DT SIN-83_NP virus_NN efficiently_RB expressed_VBD the_DT structural_JJ proteins_NNS of_IN the_DT same_JJ molecular_JJ weight_NN as_IN those_DT of_IN VEEV_NP TC-83_NP ._SENT In_IN pulse-labeling_NN experiments_NNS ,_, the_DT presence_NN of_IN the_DT additional_JJ protein_NN bands_NNS corresponding_JJ to_TO SINV_NP nsP2_NP and_CC P123_NP was_VBD detected_VBN in_IN lysate_NNS of_IN SIN-83_NP virus-infected_JJ cells_NNS ._SENT This_DT could_MD be_VB an_DT indication_NN that_IN packaging_NN of_IN the_DT chimeric_JJ genome_NN into_IN nucleocapsids_NNS was_VBD probably_RB less_RBR efficient_JJ than_IN packaging_NN of_IN SINV_NP and_CC VEEV_NP genomes_NNS by_IN homologous_JJ structural_JJ proteins_NNS ._SENT Examination_NN of_IN RNA_NP replication_NN and_CC transcription_NN showed_VBD that_IN all_DT of_IN the_DT cis-acting_JJ elements_NNS in_IN the_DT genome_NN of_IN the_DT recombinant_JJ SIN-83_NP virus_NN were_VBD fully_RB functional_JJ ,_, and_CC the_DT subgenomic_JJ RNAs_NP demonstrated_VBD expected_VBN differences_NNS in_IN sizes_NNS :_: 4,106_CD ,_, 3,915_CD ,_, and_CC 4,171_CD nt_NNS [_SYM without_IN poly(A)_JJ tail_NN ]_SYM for_IN SIN_NP Toto1101_NP ,_, VEE_NP TC-83_NP ,_, and_CC SIN-83_NP viruses_NNS ,_, respectively_RB ._SENT In_IN multiple_JJ experiments_NNS ,_, the_DT rates_NNS of_IN VEEV_NP TC-83_NP genome_NN replication_NN and_CC synthesis_NN of_IN the_DT subgenomic_JJ RNA_NP were_VBD always_RB lower_JJR than_IN those_DT of_IN SINV_NP Toto1101_NP and_CC SIN-83_NP ._SENT This_DT less_JJR efficient_JJ RNA_NP replication_NN level_NN was_VBD in_IN agreement_NN with_IN slower_JJR CPE_NN development_NN but_CC contradicted_VBD the_DT rates_NNS of_IN virus_NN release_NN ._SENT Immunization_NN with_IN SIN-83_NP virus_NN protects_VBZ mice_NNS against_IN VEEV_NP challenge_NN ._SENT |_SYM To_TO compare_VB the_DT immunogenicity_NN of_IN the_DT recombinant_JJ SIN-83_NP and_CC VEE_NP TC-83_NP viruses_NNS ,_, 6-day-old_JJ NIH_NP Swiss_JJ mice_NNS were_VBD infected_VBN s.c._JJ with_IN both_DT viruses_NNS at_IN doses_NNS ranging_VBG from_IN 103_CD to_TO 106_CD PFU_NN (_( see_VB Materials_NNS and_CC Methods_NNS for_IN details_NNS )_) ._SENT After_IN 28_CD days_NNS ,_, we_PP detected_VBD VEEV-specific_JJ neutralizing_VBG antibodies_NNS in_IN the_DT sera_NN of_IN both_DT groups_NNS ,_, although_IN the_DT titers_NNS in_IN VEEV_NP TC-83-immunized_NP animals_NNS were_VBD higher_JJR ._SENT This_DT was_VBD not_RB surprising_JJ ,_, considering_VBG the_DT higher_JJR replication_NN levels_NNS of_IN this_DT virus_NN in_IN cell_NN culture_NN ._SENT Other_JJ immunized_VBN animals_NNS were_VBD challenged_VBN with_IN 106_NP PFU_NP (_( similar106_NP LD50_NP )_) of_IN VEEV_NP strain_NN ZPC738_NP (_( subtype_NN ID_NN )_) or_CC SH3_NP (_( subtype_NN IC_NP )_) ._SENT All_DT of_IN the_DT mice_NNS survived_VBD ,_, regardless_RB of_IN the_DT doses_NNS of_IN SIN-83_NP and_CC VEE_NP TC-83_NP viruses_NNS used_VBN for_IN immunization_NN (_( 103_CD ,_, 104_CD ,_, 105_CD ,_, and_CC 106_CD PFU_NN )_) ._SENT After_IN challenge_NN ,_, none_NN of_IN the_DT animals_NNS developed_VBD any_DT detectable_JJ clinical_JJ symptoms_NNS of_IN VEE_NP for_IN more_JJR than_IN 2_CD months_NNS ,_, the_DT entire_JJ period_NN of_IN observation_NN ._SENT All_DT of_IN the_DT mice_NNS from_IN the_DT nonimmunized_JJ control_NN group_NN were_VBD hunched_VBN and_CC less_RBR active_JJ on_IN day_NN 3_CD or_CC 4_CD postinfection_NN with_IN either_CC the_DT ZPC738_NP strain_NN or_CC the_DT SH3_NP strain_NN of_IN VEEV_NP ._SENT Between_IN days_NNS 4_CD and_CC 7_CD ,_, the_DT nonimmunized_JJ mice_NNS developed_VBD anorexia_NN ,_, lethargy_NN ,_, and_CC hind_JJ limb_NN paralysis_NN ,_, and_CC the_DT CNS_NP symptoms_NNS always_RB progressed_VBD to_TO stupor_NN and_CC finally_RB to_TO coma_NN ._SENT Except_IN for_IN one_CD animal_NN infected_VBN with_IN the_DT SH3_NP strain_NN (_( death_NN on_IN day_NN 8_CD postinfection_NN )_) ,_, all_DT animals_NNS died_VBD by_IN day_NN 7_CD ._SENT The_DT cause_NN of_IN death_NN was_VBD confirmed_VBN by_IN isolating_VBG VEEV_NP from_IN the_DT brains_NNS ._SENT The_DT results_NNS of_IN these_DT experiments_NNS indicated_VBD that_IN the_DT chimeric_JJ SIN-83_NP virus_NN could_MD replicate_VB in_IN vivo_RB and_CC generate_VB an_DT effective_JJ immune_JJ response_NN against_IN VEEV_NP challenge_NN ,_, with_IN an_DT efficiency_NN similar_JJ to_TO that_DT of_IN the_DT VEEV_NP vaccine_NN strain_NN TC-83_NP ._SENT Comparative_JJ virulence_NN of_IN TC-83_NP versus_CC SIN-83_NP ._SENT |_SYM To_TO compare_VB the_DT virulence_NN of_IN the_DT VEE_NP TC-83_NP and_CC SIN-83_NP viruses_NNS ,_, 6-day-old_JJ mice_NNS were_VBD inoculated_VBN i.c._JJ or_CC s.c._JJ with_IN different_JJ doses_NNS of_IN each_DT virus_NN ranging_VBG from_IN 2_CD x_NN 104_CD to_TO 2_CD x_SYM 106_CD PFU_NN (_( see_VB Materials_NNS and_CC Methods_NNS )_) ._SENT As_IN shown_VBN in_IN Fig._NN ,_, VEEV_NP TC-83_NP was_VBD virulent_JJ for_IN weanling_NN mice_NNS regardless_RB of_IN the_DT inoculation_NN route_NN ._SENT The_DT i.c._JJ injection_NN of_IN 2_CD x_SYM 106_CD PFU_NP of_IN VEEV_NP TC-83_NP caused_VBD 100_CD %_NN mortality_NN ._SENT A_DT 10-fold-lower_JJ dose_NN was_VBD also_RB uniformly_RB lethal_JJ ,_, but_CC survival_NN time_NN was_VBD noticeably_RB longer_RBR ._SENT A_DT lower_JJR mortality_NN level_NN was_VBD observed_VBN in_IN the_DT TC-83_NP group_NN that_WDT received_VBD 2_CD x_SYM 104_CD PFU_NP i.c._NP ,_, and_CC only_RB one_CD animal_NN died_VBD ._SENT However_RB ,_, it_PP should_MD be_VB noted_VBN that_IN CNS_NP sequelae_NNS ,_, including_VBG ataxia_NN and/or_CC paralysis_NN ,_, developed_VBN in_IN seven_CD out_RB of_IN nine_CD mice_NNS infected_JJ i.c._NN with_IN 2_CD x_SYM 104_CD PFU_NP of_IN VEEV_NP TC-83_NP ._SENT Animals_NNS surviving_VBG the_DT i.c._JJ inoculation_NN were_VBD also_RB much_RB smaller_JJR when_WRB compared_VBN to_TO the_DT animals_NNS of_IN the_DT same_JJ age_NN from_IN the_DT SIN-83_NP virus-inoculated_JJ group_NN (_( data_NNS not_RB shown_VBN )_) ._SENT None_NN of_IN the_DT animals_NNS inoculated_VBN with_IN SIN-83_NP virus_NN died_VBD or_CC developed_VBD any_DT CNS_NP signs_NNS or_CC sequelae_NNS for_IN at_IN least_JJS 21_CD days_NNS postinfection_NN ._SENT VEEV_NP TC-83_NP was_VBD less_RBR pathogenic_JJ for_IN weanling_NN mice_NNS after_IN s.c._JJ inoculation_NN (_( mortality_NN rate_NN ,_, 10_CD to_TO 20_CD %_NN )_) ,_, but_CC many_JJ of_IN the_DT surviving_VBG animals_NNS developed_VBD clinical_JJ disease_NN and/or_CC CNS_NP sequelae_NNS (_( three_CD of_IN eight_CD for_IN 106_CD PFU_NP inoculum_NN ,_, three_CD of_IN nine_CD for_IN 105_CD ,_, and_CC four_CD of_IN nine_CD for_IN 104_CD PFU_NN )_) ._SENT None_NN of_IN the_DT SIN-83-inoculated_JJ animals_NNS had_VBD detectable_JJ clinical_JJ illness_NN ._SENT We_PP also_RB monitored_VBD the_DT body_NN weights_NNS of_IN mice_NNS for_IN 6_CD weeks_NNS after_IN s.c._JJ inoculation_NN with_IN 2_CD x_SYM 106_CD PFU_NP of_IN either_DT VEE_NP TC-83_NP or_CC SIN-83_NP virus_NN ._SENT Animals_NNS infected_VBN with_IN VEEV_NP TC-83_NP at_IN the_DT age_NN of_IN 6_CD days_NNS were_VBD highly_RB inhibited_VBN in_IN their_PP$ growth_NN compared_VBN to_TO those_DT infected_JJ with_IN SIN-83_NP or_CC compared_VBN to_TO the_DT noninfected_JJ control_NN group_NN of_IN the_DT same_JJ age_NN ._SENT The_DT most_RBS pronounced_JJ difference_NN in_IN body_NN weight_NN was_VBD between_IN 2_CD and_CC 4_CD weeks_NNS postinfection_NN ._SENT At_IN the_DT age_NN of_IN 6_CD weeks_NNS (_( 5_CD weeks_NNS postinfection_NN )_) ,_, the_DT difference_NN became_VBD insignificant_JJ ,_, indicating_VBG that_IN mice_NNS were_VBD able_JJ to_TO compensate_VB for_IN the_DT initial_JJ body_NN weight_NN loss_NN ._SENT SIN-83-infected_JJ mice_NNS did_VBD not_RB exhibit_VB any_DT weight_NN loss_NN compared_VBN to_TO the_DT uninfected_JJ control_NN group_NN ._SENT Recent_JJ VEE_NP epidemics_NNS and_CC equine_JJ epizootics_NNS ,_, as_RB well_RB as_IN the_DT novel_JJ threat_NN from_IN bioterrorism_NN ,_, have_VBP underscored_VBN the_DT need_NN for_IN a_DT safe_JJ and_CC effective_JJ vaccine_NN ._SENT Previously_RB ,_, the_DT attenuated_JJ VEEV_NP TC-83_NP (_( United_NP States_NPS )_) strain_NN and_CC VEEV_NP strain_NN 230_CD (_( former_JJ Union_NN of_IN Soviet_NP Socialist_NP Republics_NP )_) were_VBD developed_VBN by_IN serial_NN passaging_VBG of_IN the_DT VEEV_NP TrD_NP in_IN guinea_NN pig_NN heart_NN cells_NNS (_( 83_CD passages_NNS )_) and_CC 230_CD passages_NNS in_IN embryonated_JJ eggs_NNS ,_, respectively_RB ._SENT The_DT main_JJ disadvantage_NN of_IN both_DT viruses_NNS is_VBZ the_DT significant_JJ residual_JJ pathogenicity_NN ._SENT For_IN example_NN ,_, vaccination_NN with_IN VEEV_NP TC-83_NP is_VBZ associated_VBN with_IN adverse_JJ effects_NNS in_IN up_IN to_TO 40_CD %_NN of_IN people_NNS ._SENT However_RB ,_, both_DT strains_NNS were_VBD used_VBN for_IN decades_NNS for_IN protection_NN of_IN laboratory_NN personnel_NNS working_VBG with_IN VEEV_NP ._SENT Viral_JJ pathogenesis_NN appears_VBZ to_TO be_VB determined_VBN by_IN multiple_JJ factors_NNS that_WDT include_VBP the_DT structure_NN of_IN the_DT glycoprotein_NN spikes_VBZ on_IN the_DT surface_NN of_IN virions_NNS and_CC the_DT ability_NN to_TO replicate_VB in_IN specific_JJ tissues_NNS and_CC interfere_VB with_IN the_DT innate_JJ antiviral_JJ response_NN at_IN the_DT cellular_JJ and_CC organismal_JJ levels_NNS ._SENT Thus_RB ,_, mutations_NNS in_IN the_DT nonstructural_JJ proteins_NNS and_CC cis-acting_JJ elements_NNS of_IN viral_JJ genomes_NNS can_MD play_VB a_DT significant_JJ role_NN in_IN virus_NN attenuation_NN ._SENT Attenuating_VBG mutations_NNS in_IN genome_NN regions_NNS other_JJ than_IN those_DT encoding_VBG the_DT structural_JJ proteins_NNS have_VBP been_VBN identified_VBN for_IN poliovirus_NN ,_, yellow_JJ fever_NN virus_NN ,_, VEEV_NP ,_, Rift_NP Valley_NP fever_NN virus_NN ,_, Semliki_NP Forest_NP virus_NN ,_, ,_, and_CC SINV_NP ,_, among_IN others_NNS ._SENT However_RB ,_, despite_IN a_DT great_JJ deal_NN of_IN accumulated_VBN data_NNS ,_, our_PP$ knowledge_NN about_IN the_DT roles_NNS of_IN the_DT nonstructural_JJ proteins_NNS in_IN viral_JJ replication_NN and_CC interaction_NN with_IN host_NN cells_NNS is_VBZ far_RB from_IN complete_JJ ._SENT This_DT is_VBZ certainly_RB true_JJ for_IN VEEV_NP as_IN well_RB ,_, and_CC the_DT strategy_NN of_IN further_JJR attenuation_NN of_IN VEEV_NP with_IN point_NN mutations_NNS in_IN the_DT genome_NN does_VBZ not_RB look_VB completely_RB predictable_JJ ._SENT In_IN addition_NN ,_, alphaviruses_NNS are_VBP known_VBN for_IN their_PP$ very_RB high_JJ mutation_NN rates_NNS ,_, and_CC the_DT stability_NN of_IN the_DT introduced_VBN attenuating_NN point_NN mutations_NNS during_IN virus_NN propagation_NN will_MD always_RB be_VB a_DT great_JJ concern_NN ._SENT In_IN the_DT present_JJ study_NN ,_, we_PP attempted_VBD to_TO develop_VB a_DT new_JJ ,_, safer_JJR ,_, attenuated_JJ alphavirus_NN that_WDT can_MD elicit_VB a_DT protective_JJ immune_JJ response_NN against_IN VEEV_NP infection_NN ._SENT The_DT rationale_NN was_VBD to_TO create_VB a_DT chimeric_JJ viral_JJ genome_NN that_WDT encodes_VBZ the_DT following_NN :_: (_( i_NP )_) the_DT replicative_JJ enzymes_NNS and_CC other_JJ RNA_NP elements_NNS essential_JJ for_IN replication_NN derived_VBN from_IN SINV_NP ,_, one_CD of_IN the_DT least_JJS human-pathogenic_JJ alphaviruses_NNS ,_, and_CC (_( ii_NNS )_) structural_JJ proteins_NNS derived_VBN from_IN the_DT attenuated_JJ TC-83_NP strain_NN of_IN VEEV_NP ._SENT The_DT idea_NN of_IN creating_VBG attenuated_JJ chimeric_JJ viruses_NNS is_VBZ not_RB new_JJ ;_: it_PP was_VBD successfully_RB applied_VBN in_IN the_DT development_NN of_IN vaccines_NNS against_IN Japanese_JJ encephalitis_NN and_CC dengue_NN viruses_NNS ,_, using_VBG the_DT 17D_JJ attenuated_JJ yellow_JJ fever_NN virus_NN genome_NN as_IN a_DT vector_NN ._SENT Chimeric_JJ tick-borne_JJ encephalitis/dengue_NN type_NN 4_CD viruses_NNS were_VBD designed_VBN for_IN vaccine_NN development_NN as_IN well_RB ._SENT Recombinants_NNS between_IN different_JJ alphaviruses_NNS were_VBD also_RB described_VBN previously_RB ._SENT (_( i_NP )_) Western_JJ equine_JJ encephalitis_NN virus_NN (_( WEEV_NP )_) is_VBZ believed_VBN to_TO be_VB a_DT natural_JJ recombinant_JJ between_IN ancestral_JJ EEE-like_JJ and_CC SIN-like_JJ viruses_NNS ._SENT (_( ii_NP )_) Chimeras_NNS between_IN distant_JJ alphaviruses_NNS ,_, SINV_NP and_CC Ross_NP River_NP virus_NN (_( RRV_NP )_) ,_, and_CC the_DT more_RBR closely_RB related_VBN eastern_JJ equine_JJ encephalitis_NN virus_NN and_CC WEEV_NP were_VBD found_VBN to_TO be_VB viable_JJ as_RB well_RB ._SENT SIN/RRV_NP chimeric_JJ viruses_NNS could_MD grow_VB to_TO high_JJ titers_NNS and_CC were_VBD mainly_RB applied_VBN to_TO the_DT study_NN of_IN interactions_NNS between_IN structural_JJ and_CC nonstructural_JJ regions_NNS in_IN alphavirus_NN genomes_NNS ._SENT However_RB ,_, they_PP were_VBD attenuated_VBN compared_VBN to_TO the_DT original_JJ SINV_NP and_CC RRV_NP strains_NNS ,_, and_CC based_VBN on_IN this_DT ,_, we_PP expected_VBD a_DT significant_JJ level_NN of_IN attenuation_NN from_IN SIN/VEE_NP recombinants_NNS ._SENT The_DT initially_RB constructed_VBN SIN/VEE_NP chimera_NN ,_, SIN-83S_NP ,_, was_VBD designed_VBN based_VBN on_IN SINV_NP Toto1101_NP and_CC VEEV_NP TC-83_NP sequences_NNS and_CC demonstrated_VBN heterogeneity_NN in_IN plaque_NN morphology_NN ,_, which_WDT indicated_VBD that_IN the_DT virus_NN was_VBD capable_JJ of_IN additional_JJ adaptation_NN ,_, resulting_VBG in_IN higher_JJR replication_NN rates_NNS ._SENT In_IN the_DT plaque-purified_JJ variant_NN that_IN we_PP used_VBD for_IN sequencing_NP ,_, the_DT large-plaque_NN phenotype_NN and_CC more_JJR efficient_JJ replication_NN were_VBD due_JJ to_TO a_DT single_JJ point_NN mutation_NN in_IN nsP2_NN ,_, S795->T_NP ._SENT However_RB ,_, we_PP cannot_MD rule_VB out_RP the_DT possibility_NN that_IN other_JJ variants_NNS forming_VBG large_JJ plaques_NNS could_MD have_VB different_JJ mutations_NNS ._SENT Because_IN it_PP was_VBD not_RB the_DT goal_NN of_IN the_DT present_JJ study_NN ,_, we_PP did_VBD not_RB explore_VB the_DT possibility_NN of_IN different_JJ mutations_NNS and_CC their_PP$ potential_JJ role_NN in_IN recognizing_VBG the_DT changed_JJ subgenomic_JJ promoter_NN or_CC in_IN other_JJ functions_NNS ,_, but_CC this_DT is_VBZ now_RB under_IN investigation_NN ._SENT The_DT redesigned_VBN chimera_NN named_VBN SIN-83_NP ,_, containing_VBG the_DT S795->T_NP mutation_NN in_IN nsP2_NN ,_, was_VBD stable_JJ and_CC could_MD replicate_VB to_TO titers_NNS similar_JJ to_TO those_DT of_IN the_DT parental_JJ viruses_NNS ,_, SINV_NP Toto1101_NP and_CC VEEV_NP TC-83_NP ,_, in_IN commonly_RB used_VBN cell_NN lines_NNS ._SENT We_PP did_VBD not_RB detect_VB alterations_NNS in_IN the_DT replication_NN of_IN the_DT genomic_JJ RNA_NP and_CC transcription_NN of_IN the_DT subgenomic_JJ 26S_JJ RNA_NP ._SENT This_DT was_VBD an_DT indication_NN that_IN all_DT of_IN the_DT cis-acting_JJ RNA_NP elements_NNS functioned_VBD properly_RB ._SENT VEEV_NP structural_JJ proteins_NNS were_VBD expressed_VBN in_IN the_DT cells_NNS infected_VBN with_IN SIN-83_NP as_IN efficiently_RB as_RB in_IN the_DT cells_NNS infected_VBN with_IN VEEV_NP TC-83_NP ,_, suggesting_VBG that_IN the_DT subgenomic_JJ RNA_NP of_IN VEEV_NP can_MD have_VB structural_JJ elements_NNS that_WDT promote_VBP its_PP$ translation_NN under_IN conditions_NNS of_IN translational_JJ shutoff_NN ,_, which_WDT occurs_VBZ in_IN both_DT VEEV-_NP and_CC SINV-infected_NP cells_NNS ._SENT This_DT was_VBD a_DT point_NN of_IN concern_NN ,_, because_IN the_DT 5'-terminal_JJ sequence_NN of_IN the_DT VEE_NP 26S_NP RNA_NP is_VBZ different_JJ from_IN the_DT same_JJ fragment_NN of_IN other_JJ alphaviruses_NNS ;_: it_PP is_VBZ 20_CD nt_NN shorter_JJR than_IN average_NN ,_, and_CC there_EX is_VBZ no_DT computer-predicted_JJ ,_, stable_JJ stem-loop_NN structure_NN in_IN the_DT sequence_NN coding_VBG the_DT amino-terminal_JJ portion_NN of_IN the_DT capsid_NN protein_NN ._SENT This_DT structural_JJ element_NN in_IN SINV_NP and_CC Semliki_NP Forest_NP virus_NN was_VBD previously_RB shown_VBN to_TO function_VB as_IN a_DT translational_JJ enhancer_NN that_WDT promotes_VBZ translation_NN of_IN viral_JJ subgenomic_JJ RNA_NP in_IN the_DT conditions_NNS of_IN virus-specific_JJ translation_NN inhibition_NN ._SENT However_RB ,_, in_IN the_DT VEEV_NP genome_NN ,_, this_DT fragment_NN remains_VBZ very_JJ G-C_NP rich_JJ and_CC appears_VBZ to_TO function_VB in_IN the_DT same_JJ fashion_NN ,_, probably_RB together_RB with_IN the_DT short_JJ 5_CD '_POS UTR_NP ,_, but_CC this_DT assumption_NN needs_VBZ further_JJR investigation_NN ._SENT SIN-83_NP virus_NN induced_VBD an_DT immune_JJ response_NN in_IN weanling_NN mice_NNS that_WDT was_VBD sufficient_JJ to_TO protect_VB them_PP against_IN high_JJ doses_NNS (_( 106_CD LD50_NP )_) of_IN subtype_NN ID_NNS and_CC IC_NP VEEV_NP strains_NNS ._SENT The_DT same_JJ protective_JJ effect_NN was_VBD confirmed_VBN in_IN adult_NN (_( 6_CD to_TO 8_CD weeks_NNS old_JJ )_) mice_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT The_DT use_NN of_IN weanling_NN mice_NNS allowed_VBD us_PP not_RB only_RB to_TO test_VB the_DT efficiency_NN of_IN the_DT immune_JJ response_NN caused_VBN by_IN SIN-83_NP but_CC also_RB to_TO compare_VB the_DT residual_JJ pathogenicity_NN of_IN this_DT virus_NN with_IN that_DT of_IN VEEV_NP TC-83_NP ._SENT SIN-83_NP was_VBD significantly_RB more_RBR attenuated_JJ ;_: i.c._JJ infection_NN with_IN 2_CD x_SYM 106_CD PFU_NP did_VBD not_RB produce_VB any_DT clinical_JJ symptoms_NNS ._SENT In_IN contrast_NN ,_, the_DT same_JJ doses_NNS of_IN TC-83_NP were_VBD lethal_JJ ,_, and_CC virus_NN was_VBD easily_RB detected_VBN in_IN mouse_NN brains_NNS ._SENT However_RB ,_, we_PP did_VBD not_RB study_VB if_IN TC-83-induced_JJ mouse_NN death_NN was_VBD a_DT result_NN of_IN additional_JJ mutations_NNS ,_, making_VBG virus_NN more_RBR pathogenic_JJ ,_, or_CC whether_IN death_NN resulted_VBN from_IN residual_JJ pathogenicity_NN ._SENT The_DT s.c._JJ administration_NN of_IN VEEV_NP TC-83_NP was_VBD less_RBR lethal_JJ than_IN i.c._JJ inoculation_NN ._SENT However_RB ,_, the_DT high_JJ rate_NN of_IN CNS_NP sequelae_NNS in_IN animals_NNS surviving_VBG TC-83_NP infection_NN ,_, after_IN either_DT s.c._JJ or_CC i.c._JJ inoculation_NN ,_, indicates_VBZ that_IN the_DT virus_NN is_VBZ able_JJ to_TO penetrate_VB into_IN the_DT CNS_NP and_CC replicate_VB efficiently_RB after_IN inoculation_NN by_IN either_DT route_NN ._SENT Virus_NN clearance_NN from_IN the_DT CNS_NNS in_IN animals_NNS surviving_VBG challenge_NN is_VBZ probably_RB associated_VBN with_IN irreparable_JJ destruction_NN of_IN neuronal_JJ tissue_NN ,_, which_WDT is_VBZ reflected_VBN in_IN the_DT high_JJ rate_NN of_IN CNS_NP sequelae_NNS ,_, such_JJ as_IN ataxia_NN and_CC paralysis_NN ._SENT The_DT cause_NN of_IN these_DT findings_NNS was_VBD not_RB investigated_VBN further_JJR but_CC could_MD be_VB a_DT result_NN of_IN more-efficient_JJ virus_NN replication_NN in_IN the_DT brain_NN ,_, rather_RB then_RB of_IN a_DT higher_JJR neurotoxicity_NN at_IN the_DT single_JJ cell_NN level_NN ._SENT Moreover_RB ,_, we_PP believe_VBP that_IN high_JJ titers_NNS of_IN neutralizing_VBG antibodies_NNS in_IN surviving_VBG animals_NNS infected_VBN with_IN TC-83_NP probably_RB reflect_VBP high_JJ levels_NNS of_IN replication_NN ,_, leading_VBG to_TO disease_NN in_IN weanling_NN mice_NNS ._SENT The_DT ability_NN of_IN TC-83_NP to_TO induce_VB clinical_JJ illness_NN was_VBD previously_RB described_VBN in_IN mice_NNS and_CC in_IN equines_NNS and_CC is_VBZ sometimes_RB comparable_JJ to_TO that_DT caused_VBN by_IN enzootic_JJ VEEV_NP strains_NNS ._SENT In_IN contrast_NN to_TO VEEV_NP TC-83_NP infection_NN ,_, animals_NNS vaccinated_VBD with_IN SIN-83_NP virus_NN did_VBD not_RB develop_VB CNS_NP symptoms_NNS or_CC sequelae_NNS ,_, even_RB upon_IN i.c._JJ inoculation_NN ,_, indicating_VBG very_RB low_JJ pathogenicity_NN of_IN this_DT chimeric_JJ virus_NN ._SENT In_IN the_DT course_NN of_IN the_DT experiments_NNS ,_, we_PP also_RB noticed_VBD that_IN prolonged_JJ alteration_NN of_IN the_DT immune_JJ system_NN or_CC other_JJ adverse_JJ VEEV_NP TC-83-induced_NP effects_NNS during_IN the_DT most_RBS intensive_JJ phase_NN of_IN animal_JJ development_NN led_VBN to_TO a_DT significant_JJ reduction_NN in_IN growth_NN ._SENT This_DT effect_NN was_VBD detectable_JJ for_IN several_JJ weeks_NNS postvaccination_NN ._SENT We_PP can_MD only_RB speculate_VB about_IN the_DT mechanisms_NNS leading_VBG to_TO slower_JJR growth_NN of_IN the_DT animals_NNS ;_: some_DT of_IN the_DT possibilities_NNS include_VBP metabolic_JJ factors_NNS ,_, such_JJ as_IN the_DT reduced_VBN energy_NN recovery_NN from_IN food_NN caused_VBN by_IN bacterial_JJ overgrowth_NN in_IN the_DT gut_NN (_( e.g._FW ,_, because_IN of_IN the_DT reduced_VBN level_NN of_IN immunoglobulin_NN A_DT )_) ,_, and_CC endocrine/exocrine_NN factors_NNS due_JJ to_TO the_DT direct_JJ viral_JJ or_CC immune-mediated_JJ effects_NNS on_IN the_DT pancreas_NN and/or_CC CNS_NP ,_, or_CC a_DT combination_NN of_IN several_JJ different_JJ factors_NNS ._SENT Further_JJR pathogenesis_NN studies_NNS with_IN young_JJ mice_NNS are_VBP needed_VBN to_TO understand_VB the_DT underlying_VBG mechanisms_NNS for_IN these_DT alterations_NNS in_IN animal_JJ development_NN ._SENT Importantly_RB ,_, SIN-83_NP did_VBD not_RB cause_VB any_DT effect_NN on_IN mouse_NN growth_NN after_IN s.c._JJ inoculation_NN of_IN 2_CD x_SYM 106_CD PFU_NP ,_, at_IN least_JJS ._SENT In_IN conclusion_NN ,_, we_PP have_VBP shown_VBN that_IN a_DT recombinant_JJ alphavirus_NN with_IN a_DT genome_NN encodi_NN 